Healthcare Slump Is a Buying Opportunity
Investors' concerns over the impacts of slowing global growth and drug pricing are overdone, leaving some quality names undervalued.
Investors' concerns over the impacts of slowing global growth and drug pricing are overdone, leaving some quality names undervalued.
Damien Conover: The healthcare sector has been one of the more underperforming sectors since the beginning of the year. There are two main drivers that are causing this pullback. First off, we're seeing a global slowdown that is impacting healthcare, and we're also seeing concerns over drug pricing, primarily in the U.S. We think that both of these issues have been overdone, and we believe in the healthcare sector. There are a lot of industries that offer compelling valuations.
Now, let's take a look at some of these concerns. First off, with the slowing global growth, we think that when you look at the elasticity of healthcare products, they are generally inelastic, meaning people don't give these products up as the markets start to slow down. So, we think healthcare will hold up reasonably well.
Second, when we think about the concerns over drug pricing in the U.S., we think this is overdone as well. While we think there could be some slight reforms, generally speaking, we don't anticipate the U.S. government to enact major reform. So, that should enable drug prices to actually hold up pretty well. Within this context, we think the large-cap pharmaceutical stocks and the biotechnology sector look undervalued in our view.
There are two names we'd recommend. The first one is Biogen Idec (BIIB). This is a firm that specializes in multiple sclerosis drugs and has a pipeline focused in Alzheimer's disease. Both of those areas should have very strong pricing power going forward.
Another name we like a lot right now is Pfizer (PFE). Pfizer is right in the midst of acquiring Allergan (AGN), which should give it a lot of faster-growing products relative to what it currently has along with a much lower tax rate.
Both of these names, we think, are significantly undervalued, and we'd advise investors to take a look.
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
We’d like to share more about how we work and what drives our day-to-day business.
We sell different types of products and services to both investment professionals
and individual investors. These products and services are usually sold through
license agreements or subscriptions. Our investment management business generates
asset-based fees, which are calculated as a percentage of assets under management.
We also sell both admissions and sponsorship packages for our investment conferences
and advertising on our websites and newsletters.
How we use your information depends on the product and service that you use and your relationship with us. We may use it to:
To learn more about how we handle and protect your data, visit our privacy center.
Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.
To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.
Read our editorial policy to learn more about our process.